Cytek will host a conference call to discuss its third quarter 2024 financial results on Tuesday, November 5, 2024, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A webcast of the conference call ...

including the Amnis® and Guava® instruments shipped since the acquisition of the flow cytometry and imaging business from Luminex Corporation in February 2023, adding 164 units in the third ...

This growth in international markets reflects the fact that Cytek Technology is the market leading full spectral flow cytometry technology of choice for research institutions and biopharma ...

In addition, Cytek continues to expect to report a net loss in the single digit millions for the full year 2024 and positive cash flow from operations in 2024. Cytek will host a conference call to ...

Cytek's flow cytometry instruments are seen as essential, differentiating from competitors. CEO Wenbin Jiang discussed progress in the U.S. clinical market, including the 510(k) process and ...

The company is experiencing a recovery in demand in North America and momentum in Europe and Asia Pacific. Cytek's flow cytometry instruments are seen as essential, differentiating from competitors.

Cloud digital ecosystem Expanded to a total installed base of 2,821 Cytek instruments, including the Amnis® and Guava® instruments shipped since the acquisition of the flow cytometry ...

Cytek Biosciences Inc (CTKB) reports a 7% revenue growth and a positive net income, while navigating softer US market conditions and maintaining strong global demand.